This is a Phase II study to evaluate the efficacy and safety of a human papilloma virus (HPV) therapeutic vaccine called PepCan (HPV 16 E6 peptides combined with Candida skin testing reagent called CandinĀ®) in adult females over a 12 month time period. As the results from the Phase I trial demonstrated some efficacy against non-16 HPV types, Candin alone will also be tested. Therefore, there will be two treatment arms: (1) PepCan and (2) Candin. Subjects found to be eligible for vaccination will be randomized in a double-blinded fashion at a 1:1 ratio. Each participant will be receiving injections four times with three weeks between injections. Clinical and virological responses will be assessed at 6 and 12 months. Safety will be assessed from the time of enrollment to 12 Month Visit. Immunological assessments will be made at 4 time points (prevaccination, after 2 injections, 6 month after 4 injections and 12 months after 4 vaccinations).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Subjects With Complete Response With the Intention-to-treat (ITT) Analysis
Timeframe: 15 months from time of last vaccination
Number of Subjects With Complete Response With the Per-protocol Analysis
Timeframe: 15 months from time of last vaccination
Number of Subjects With Complete and Partial Responses With the ITT Analysis
Timeframe: 15 months from time of last vaccination
Number of Subjects With Complete and Partial Responses With the Per-protocol Analysis
Timeframe: 15 months from time of last vaccination